IBJNews

Lilly's Alzheimer's drug trials show mixed results

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.

The Indianapolis-based drugmaker announced the mixed clinical trial results Friday morning. The drug, called solanezumab, was studied in a total of more than 2,000 patients with mild or moderate Alzheimer’s disease.

The drugmaker's stock rose 7.5 percent  in premarket trading.

Lilly’s analysis of the data after the trial showed that solanezumab slowed cognitive decline in mild Alzheimer’s patients but not in moderate ones.

The finding, in a subgroup of patients, wasn’t expected by analysts and investors, who had given the drug a less than 20 percent chance of showing any benefit.

That finding is a first for any drug trying to combat the memory-sapping malady, which afflicts 5 million Americans and 18 million people worldwide. Lilly is trying to make solanezumab the first drug to successfully fight the progress of Alzheiemr’s disease, which, if successful, is almost certain to generate billions of dollars per year in sales.

A similar-acting medicine from Pfizer Inc. and Johnson & Johnson failed to show a benefit earlier this month. If approved for a wide population of Alzheimer’s sufferers, the treatment may “transform” Lilly and bring in $5 billion to $10 billion in annual sales, said Goldman Sachs analyst Jami Rubin in a note to clients last month. That would be much needed revenue for Lilly as it braces to lose $7 billion from generic competition over the next five years.

"We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline," said Lilly CEO John Lechleiter in a prepared statement. "We intend to discuss these data with regulatory authorities to gain their insights on potential next steps."

That could include another clinical trial of solanezumab aimed at patients with who have yet to develop full-blown Alzheimer’s symptoms. That’s because recent research has shown that that suspected causes of Alzheimer’s disease begin 10 or even 20 years before a patient can be diagnosed with the disease.

Lilly’s drug solanezumab fights Alzheimer’s by trying to remove a protein called amyloid beta from patients’ brains. The build-up amyloid into clumps and plaques is believed by many to stop the functioning of neurons, leading to memory loss and eventually death.

The only other therapy in late-stage testing is Baxter International Inc.’s Gammagard. The product is an expensive, relatively scarce treatment derived from donated blood plasma that replaces antibodies in people whose immune systems can’t protect them from infection. Results from a final-stage study on whether it could slow or stop Alzheimer’s may be available next year.

Lilly lost patent protection last year on its top-seller Zyprexa for schizophrenia and will lose the patent next year for its second-best seller, the anti-depressant Cymbalta. The drugs combined for 36 percent of Lilly’s 2011 revenue.

Lechleiter has said the company’s annual revenue will not be less than $20 billion and profit will remain more than $3 billion through 2014. In 2011, Lilly brought in revenue of $24.3 billion with a profit of $4.35 billion.

Lilly has 11 other medicines in late-stage testing, six of which may generate more than $1 billion each in peak annual sales, said Jeffrey Holford, an analyst with Jefferies Group Inc. in New York. Sales from those drugs won’t come soon enough to overcome the losses Lilly faces through at least 2017, he said.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Can your dog sign a marriage license or personally state that he wishes to join you in a legal union? If not then no, you cannot marry him. When you teach him to read, write, and speak a discernible language, then maybe you'll have a reasonable argument. Thanks for playing!

  2. Look no further than Mike Rowe, the former host of dirty jobs, who was also a classically trained singer.

  3. Current law states income taxes are paid to the county of residence not county of income source. The most likely scenario would be some alteration of the income tax distribution formula so money earned in Marion co. would go to Marion Co by residents of other counties would partially be distributed to Marion co. as opposed to now where the entirety is held by the resident's county.

  4. This is more same-old, same-old from a new generation of non-progressive 'progressives and fear mongers. One only needs to look at the economic havoc being experienced in California to understand the effect of drought on economies and people's lives. The same mindset in California turned a blind eye to the growth of population and water needs in California, defeating proposal after proposal to build reservoirs, improve water storage and delivery infrastructure...and the price now being paid for putting the demands of a raucous minority ahead of the needs of many. Some people never, never learn..

  5. I wonder if I can marry him too? Considering we are both males, wouldn't that be a same sex marriage as well? If they don't honor it, I'll scream discrimination just like all these people have....

ADVERTISEMENT